MARCO and neoplasm: Recently, it was reported that anti-MARCO mAbs suppressed angiogenesis, switched the metabolic program of MARCO+ TAMs, induced NK-cell killing through TNF-related apoptosis-inducing ligand (TRAIL) and synergized with anti-PD-1/PD-L1 mAb therapy, to enhance tumor suppression [183].